Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response 

Results, presented simultaneously in oral presentation at ASCO…Read More

You might also be interested in reading Conduent outlines 5%–5.5% adjusted EBITDA margin target for 2025 as portfolio rationalization advances.